Click the icons below to search through Pioneer’s reports and documents.
|Date added||May 21, 2020|
|Category||Health Care, Life Sciences, White Papers|
Date: May 21, 2020
Author: William Smith
Contrary to conventional wisdom that says the coronavirus pandemic will generally benefit biopharmaceutical companies, a new Pioneer Institute study finds many companies will emerge from the pandemic commercially weaker, dealing with delays in new product launches and with fewer resources to invest in research and development.